Evidence map›Paper›PMID 38434192›Full record

ArticleSovremennye tekhnologii v meditsine2023

New Tissue-Engineered Vascular Matrix Based on Regenerated Silk Fibroin:

E S Prokudina, E A Senokosova, L V Antonova, E O Krivkina, E A Velikanova, T N Akentieva, T V Glushkova, V G Matveeva, N A Kochergin

Open access · diamondAbstract read
In one paragraph

Article in Sovremennye tekhnologii v meditsine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

E S ProkudinaResearcher, Laboratory of Tissue Engineering and Intravascular Visualization; Research Institute for Complex Issues in Cardiovascular Diseases, 6 Sosnovy Blvd., Kemerovo, 650002, Russia.
E A SenokosovaResearcher, Laboratory of Tissue Engineering and Intravascular Visualization; Research Institute for Complex Issues in Cardiovascular Diseases, 6 Sosnovy Blvd., Kemerovo, 650002, Russia.
L V AntonovaLeading Researcher, Laboratory of Tissue Engineering and Intravascular Visualization; Research Institute for Complex Issues in Cardiovascular Diseases, 6 Sosnovy Blvd., Kemerovo, 650002, Russia.
E O KrivkinaJunior Researcher, Laboratory for Cell Technology; Research Institute for Complex Issues in Cardiovascular Diseases, 6 Sosnovy Blvd., Kemerovo, 650002, Russia.
E A VelikanovaResearcher, Laboratory for Cell Technology; Research Institute for Complex Issues in Cardiovascular Diseases, 6 Sosnovy Blvd., Kemerovo, 650002, Russia.
T N AkentievaJunior Researcher, Laboratory of New Biomaterials; Research Institute for Complex Issues in Cardiovascular Diseases, 6 Sosnovy Blvd., Kemerovo, 650002, Russia.
T V GlushkovaSenior Researcher, Laboratory of New Biomaterials; Research Institute for Complex Issues in Cardiovascular Diseases, 6 Sosnovy Blvd., Kemerovo, 650002, Russia.
V G MatveevaSenior Researcher, Laboratory for Cell Technology; Research Institute for Complex Issues in Cardiovascular Diseases, 6 Sosnovy Blvd., Kemerovo, 650002, Russia.
N A KocherginHead of Laboratory of Tissue Engineering and Intravascular Visualization Research Institute for Complex Issues in Cardiovascular Diseases, 6 Sosnovy Blvd., Kemerovo, 650002, Russia.
Kemerovo State University · RUCell Technology (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Materials and Methods: Tissue-engineered matrices were produced by electrospinning. The surface structure, physical and mechanical characteristics, hemocompatibility (erythrocyte hemolysis, aggregation, adhesion and activation of platelets after contact with the material) and matrix properties of vascular patches (adhesion, viability, metabolic activity of EA.hy926 cells on the material) were studied. Results: The surface of SF-based matrices and PHBV/PCL/VEGF-based tissue engineered patches had a porous and fibrous structure compared to a denser and more uniform XP flap. The physical and mechanical characteristics of SF matrices were close to those of native vessels. Along with this, tissue-engineered patches demonstrated high hemocompatible properties, which do not differ from those for commercial XP flap. Adhesion, viability, and metabolic activity of EA.hy926 endothelial cells also corresponded to the previously developed PHBV/PCL/VEGF matrix and XP flap, which indicates the nontoxicity and biocompatibility of SF matrices. Conclusion: Matrices produced from regenerated SF demonstrated satisfactory results, comparable to those for PHBV/PCL/VEGF and commercial XP flap, and in the case of platelet adhesion and activation, they outperformed these patches. In total, SF can be defined as material having sufficient biological compatibility, which makes it possible to consider a tissue-engineered matrix made from it as promising for implantation into the vascular wall.

Indexed as

Endothelial CellsFibroinsAnimalsCattlePolyestersResearch DesignVascular Endothelial Growth Factor AFibroinsPolyestersVascular Endothelial Growth Factor Abiocompatibilityelectrospinningsilk fibrointissue engineeringvascular patch

Identifiers

PMID38434192
PMCPMC10902900
OpenAlexW4386294577

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.